Pulmonary nodule assessment after PET-CT

Herder Pulmonary Nodule Risk Calculator

Estimate lung nodule malignancy risk using clinical findings, CT features, and qualitative FDG uptake on PET-CT. The calculator shows the Mayo/Swensen baseline and the Herder probability together.

For adult solid pulmonary nodule assessment after PET-CT. Calculations run in your browser. No patient identifiers are needed.

Enter clinical, CT, and PET findings

Complete every field using the reports for the same nodule.

Adult calculator range, 18–100 years.

Use maximum diameter on CT, rather than an averaged diameter.

Current or former smoker
Previous extrathoracic cancer

Any previous cancer outside the thorax, following the BTS calculator convention. See the model notes below.

Upper-lobe location
Spiculation
FDG uptake on PET-CT

Use the report’s qualitative category. A PET scan with absent uptake is different from a PET scan that has not been done.

Herder risk estimate

Complete the inputs to see the Mayo baseline and the updated probability after PET-CT.

Brock vs. Herder for pulmonary nodule risk

Initial CT assessment

The Brock pulmonary nodule risk calculator uses clinical and CT predictors for an initial estimate. The published 2015 BTS pathway uses Brock to help select appropriate nodules for PET-CT.

Reassessment after PET-CT

Herder adds the PET finding to a Mayo/Swensen clinical estimate. Enter the clinical predictors again here so the appropriate baseline is calculated. Original Herder study

For eligible incidental nodules, the Fleischner nodule follow-up assistant provides a separate surveillance reference. Model probabilities and follow-up guidance answer different clinical questions.

How the Herder score is calculated

1. Calculate the Mayo/Swensen baseline

M = −6.8272 + (0.0391 × age) + (0.7917 × smoker) + (1.3388 × previous cancer) + (0.1274 × diameter) + (1.0407 × spiculation) + (0.7838 × upper lobe)

pMayo = 1 ÷ (1 + exp(−M))

Age is in years and maximum diameter is in millimeters. Binary predictors are 1 for Yes and 0 for No. Previous cancer follows the BTS convention described below. Mayo equation and validation

2. Add the qualitative PET category

H = −4.739 + (3.691 × pMayo) + PET coefficient

Herder risk (%) = 100 ÷ (1 + exp(−H))

Use the Mayo probability as a fraction from 0 to 1. PET coefficients are 0 for absent uptake, 2.322 for faint, 4.617 for moderate, and 4.771 for intense. Apply one category. Published equations

Worked Herder calculation example

For a 65-year-old current or former smoker with a 20 mm upper-lobe nodule, no spiculation, and no previous extrathoracic cancer, the Mayo baseline is 45.95%. Moderate PET uptake gives a Herder estimate of 82.84%. This example illustrates the equation rather than a treatment recommendation.

Model applicability and interpretation

Which previous-cancer history is used?

This calculator follows the BTS implementation and counts any previous extrathoracic cancer. The original model used a history at least five years earlier and excluded more recent diagnoses. The distinction matters when comparing calculators. BTS model notes

Does absent FDG uptake rule out cancer?

No. Small nodules and some malignancies have low FDG uptake. Infection and inflammation can also produce uptake. Interpret PET findings alongside CT and the full clinical assessment. PET study and limitations

When does the model need extra caution?

The original Herder study involved 106 referred patients. Performance can vary in other populations. Ground-glass and part-solid nodules need morphology-specific assessment, and PET reliability depends on nodule size and tumor biology. This tool supports adult solid-nodule assessment and accepts a maximum diameter of 1–30 mm. An accepted input range does not establish model suitability for every nodule. Herder study · BTS guideline

What does the result mean for management?

The result is an estimated malignancy probability. The treating team considers growth, prior imaging, fitness, patient preferences, and local pathways when choosing surveillance, further testing, or treatment. Published BTS pathway

Clinical references

Sources checked November 17, 2026. The 2015 BTS publication is cited for pathway context. The October 2026 update is a public consultation draft.